Hyperforin-loaded gold nanoparticle alleviates experimental autoimmune encephalomyelitis by suppressing Th1 and Th17 cells and upregulating regulatory T cells

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 12, Issue 7, 2016, Pages 1961-1971

  Nosratabadi, Reza ^a   Rastin, Maryam ^b   Sankian, Mojtaba ^b   Haghmorad, Dariush ^b   Mahmoudi, Mahmoud ^b  

^a RAFSANJAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Experimental autoimmune encephalomyelitis (EAE); Gold nanoparticle; Hyperforin; Multiple sclerosis; Myelin oligodendrocyte glycoprotein (MOG)

Indexed keywords

CELLS; CYTOLOGY; GOLD; MEDICAL APPLICATIONS; METAL NANOPARTICLES; NANOPARTICLES;

EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; GOLD NANOPARTICLES; HYPERFORINS; MULTIPLE SCLEROSIS; OLIGODENDROCYTES;

T-CELLS;

GAMMA INTERFERON; GOLD NANOPARTICLE; HYPERFORIN; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 4; INTERLEUKIN 6; TRANSCRIPTION FACTOR FOXP3; TRANSCRIPTION FACTOR GATA 3; TRANSFORMING GROWTH FACTOR BETA; GOLD; NANOPARTICLE; PHLOROGLUCINOL; TERPENE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATOMIC FORCE MICROSCOPY; CD4+ CD25+ T LYMPHOCYTE; CELL COUNT; CELL INFILTRATION; CELL POPULATION; CONTROLLED STUDY; CYTOKINE RESPONSE; CYTOTOXICITY; DRUG MEGADOSE; DRUG RELEASE; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; FEMALE; HISTOPATHOLOGY; HYDRODYNAMICS; IN VITRO STUDY; INFLAMMATORY CELL; LOW DRUG DOSE; LYMPHOCYTE DIFFERENTIATION; MOUSE; MULTIPLE SCLEROSIS; NANOPHARMACEUTICS; NONHUMAN; PARTICLE SIZE; PHOTON CORRELATION SPECTROSCOPY; REGULATORY T LYMPHOCYTE; SPLEEN CELL; TH1 CELL; TH17 CELL; TH2 CELL; UPREGULATION; ANALOGS AND DERIVATIVES; ANIMAL; C57BL MOUSE; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL;

ANIMALS; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; GOLD; MICE; MICE, INBRED C57BL; NANOPARTICLES; PHLOROGLUCINOL; T-LYMPHOCYTES, REGULATORY; TERPENES; TH1 CELLS; TH17 CELLS;

EID: 84973864242     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2016.04.001     Document Type: Article

References (45)

1. Stadelmann C., Wegner C., Brück W. Inflammation, demyelination, and degeneration-recent insights from MS pathology. Biochim Biophys Acta 2011, 1812(2):275-282.
2. Zuvich R., McCauley J., Pericak-Vance M., Haines J. Genetics and pathogenesis of multiple sclerosis. Paper presented at: Seminars in immunology 2009.
3. Fletcher J., Lalor S., Sweeney C., Tubridy N., Mills K. T cells in multiple sclerosis and experimental autoimmune encephalomyelitis. Clin Exp Immunol 2010, 162(1):1-11.
4. Lovett-Racke A.E., Yang Y., Racke M.K. Th1 versus Th17: are T cell cytokines relevant in multiple sclerosis?. Biochim Biophys Acta Feb 2011, 1812(2):246-251.
5. Crane I.J., Forrester J.V. Th1 and Th2 lymphocytes in autoimmune disease. Crit Rev Immunol 2005, 25(2).
6. Paul W.E., Zhu J. How are TH2-type immune responses initiated and amplified?. Nat Rev Immunol 2010, 10(4):225-235.
7. Yagi R., Zhu J., Paul W.E. An updated view on transcription factor GATA3-mediated regulation of Th1 and Th2 cell differentiation. Int Immunol 2011, 23(7):415-420.
8. Kanhere A., Hertweck A., Bhatia U., et al. T-bet and GATA3 orchestrate Th1 and Th2 differentiation through lineage-specific targeting of distal regulatory elements. Nat Commun 2012, 3:1268.
9. Zhu J., Paul W.E. Peripheral CD4+ T-cell differentiation regulated by networks of cytokines and transcription factors. Immunol Rev 2010, 238(1):247-262.
10. Singh B., Schwartz J.A., Sandrock C., Bellemore S.M., Nikoopour E. Modulation of autoimmune diseases by interleukin (IL)-17 producing regulatory T helper (Th17) cells. Indian J Med Res 2013, 138(5):591.
11. Batoulis H., Addicks K., Kuerten S. Emerging concepts in autoimmune encephalomyelitis beyond the CD4/TH 1 paradigm. Ann Anat 2010, 192(4):179-193.
12. Moudgil K.D., Choubey D. Cytokines in autoimmunity: role in induction, regulation, and treatment. J Interf Cytokine Res 2011, 31(10):695-703.
13. Venkatesha S.H., Dudics S., Acharya B., Moudgil K.D. Cytokine-modulating strategies and newer cytokine targets for arthritis therapy. Int J Mol Sci 2014, 16(1):887-906.
14. Azizi G., Mirshafiey A. The potential role of proinflammatory and antiinflammatory cytokines in Alzheimer disease pathogenesis. Immunopharmacol Immunotoxicol 2012, 34(6):881-895.
15. Brown S.A. Alternative medicine and multiple sclerosis. Int J MS Care 2001, 3(3):15-20.
16. Zanoli P. Role of hyperforin in the pharmacological activities of St. John's wort. CNS Drug Rev 2004, 10(3):203-218.
17. Koeberle A., Rossi A., Bauer J., et al. Hyperforin, an anti-inflammatory constituent from St. John's wort, inhibits microsomal prostaglandin E2 synthase-1 and suppresses prostaglandin E2 formation in vivo. Front Pharmacol 2011, 2.
18. Meinke M.C., Schanzer S., Haag S.F., et al. In vivo photoprotective and anti-inflammatory effect of hyperforin is associated with high antioxidant activity in vitro and ex vivo. Eur J Pharm Biopharm 2012, 81(2):346-350.
19. Yuan F., Thiele G.M., Wang D. Nanomedicine development for autoimmune diseases. Drug Dev Res 2011, 72(8):703-716.
20. Tiwari P.M., Vig K., Dennis V.A., Singh S.R. Functionalized gold nanoparticles and their biomedical applications. Nanomaterials 2011, 1(1):31-63.
21. Spivak M.Y., Bubnov R.V., Yemets I.M., Lazarenko L.M., Timoshok N., Ulberg Z.R. Gold nanoparticles-the theranostic challenge for PPPM: nanocardiology application. EPMA J 2013, 4(1):18.
22. Zabetakis K., Ghann W.E., Kumar S., Daniel M.-C. Effect of high gold salt concentrations on the size and polydispersity of gold nanoparticles prepared by an extended Turkevich-Frens method. Gold Bull 2012, 45(4):203-211.
23. Nosratabadi R., Rastin M., Sankian M., et al. St. John's wort and its component hyperforin alleviate experimental autoimmune encephalomyelitis through expansion of regulatory T-cells. J Immunotoxicol 2015, 1-11.
24. Daniel M.-C., Astruc D. Gold nanoparticles: assembly, supramolecular chemistry, quantum-size-related properties, and applications toward biology, catalysis, and nanotechnology. Chem Rev 2004, 104(1):293-346.
25. Aziz M., Suwanpayak N., Jalil M.A., et al. Gold nanoparticle trapping and delivery for therapeutic applications. Int J Nanomedicine 2012, 7:11.
26. Rosi N.L., Mirkin C.A. Nanostructures in biodiagnostics. Chem Rev 2005, 105(4):1547-1562.
27. Sanna V., Pala N., Dessì G., et al. single-step green synthesis and characterization of gold-conjugated polyphenol nanoparticles with antioxidant and biological activities. Int J Nanomedicine 2014, 9:4935.
28. Hsieh D.-S., Wang H., Tan S.-W., et al. The treatment of bladder cancer in a mouse model by epigallocatechin-3-gallate-gold nanoparticles. Biomaterials 2011, 32(30):7633-7640.
29. Coffman R.L. Origins of the TH1-TH2 model: a personal perspective. Nat Immunol 2006, 7(6):539-541.
30. Cabrelle A., Dell'Aica I., Melchiori L., et al. Hyperforin down-regulates effector function of activated T lymphocytes and shows efficacy against Th1-triggered CNS inflammatory-demyelinating disease. J Leukoc Biol 2008, 83(1):212-219.
31. Yeh W.-I., McWilliams I.L., Harrington L.E. Autoreactive Tbet-positive CD4 T cells develop independent of classic Th1 cytokine signaling during experimental autoimmune encephalomyelitis. J Immunol 2011, 187(10):4998-5006.
32. Miossec P., Kolls J.K. Targeting IL-17 and TH17 cells in chronic inflammation. Nat Rev Drug Discov 2012, 11(10):763-776.
33. Zhu S., Pan W., Shi P., et al. Modulation of experimental autoimmune encephalomyelitis through TRAF3-mediated suppression of interleukin 17 receptor signaling. J Exp Med 2010, 207(12):2647-2662.
34. Tesmer L.A., Lundy S.K., Sarkar S., Fox D.A. Th17 cells in human disease. Immunol Rev 2008, 223(1):87-113.
35. Shiner E.K., Holbrook B.C., Alexander-Miller M.A. CD4+ T cell subset differentiation and avidity setpoint are dictated by the interplay of cytokine and antigen mediated signals. PLoS One 2014, 9(6).
36. Korn T., Bettelli E., Oukka M., Kuchroo V.K. IL-17 and Th17 cells. Annu Rev Immunol 2009, 27:485-517.
37. Yosef N., Shalek A.K., Gaublomme J.T., et al. Dynamic regulatory network controlling TH17 cell differentiation. Nature 2013, 496(7446):461-468.
38. Selim M.E., Abd-Elhakim Y.M., Al-Ayadhi L.Y. Pancreatic response to gold nanoparticles includes decrease of oxidative stress and inflammation in autistic diabetic model. Cell Physiol Biochem 2015, 35(2):586-600.
39. Dell'Aica I., Niero R., Piazza F., et al. Hyperforin blocks neutrophil activation of matrix metalloproteinase-9, motility and recruitment, and restrains inflammation-triggered angiogenesis and lung fibrosis. J Pharmacol Exp Ther 2007, 321(2):492-500.
40. Griffith T., Varela-Nallar L., Dinamarca M., Inestrosa N. Neurobiological effects of hyperforin and its potential in Alzheimer's disease therapy. Curr Med Chem 2010, 17(5):391-406.
41. Lin Y., Zhang J.-C., Fu J., et al. Hyperforin attenuates brain damage induced by transient middle cerebral artery occlusion (MCAO) in rats via inhibition of TRPC6 channels degradation. J Cereb Blood Flow Metab 2013, 33(2):253-262.
42. Zhou C., Tabb M.M., Sadatrafiei A., GRUeN F., Sun A., Blumberg B. Hyperforin, the active component of St. John's wort, induces IL-8 expression in human intestinal epithelial cells via a MAPK-dependent, NF-κB-independent pathway. J Clin Immunol 2004, 24(6):623-636.
43. Bork P.M., Bacher S., Schmitz M.L., Kaspers U., Heinrich M. Hypericin as a non-antioxidant inhibitor of NF-kappa B. Planta Med 1999, 65(4):297-300.
44. Koeberle A., Rossi A., Bauer J., et al. Hyperforin, an anti-inflammatory constituent from St. John's wort, inhibits microsomal prostaglandin E(2) synthase-1 and suppresses prostaglandin E(2) formation in vivo. Front Pharmacol 2011, 2:7.
45. Ayoub S.S., Wood E.G., Hassan S.U., Bolton C. Cyclooxygenase expression and prostaglandin levels in central nervous system tissues during the course of chronic relapsing experimental autoimmune encephalomyelitis (EAE). Inflamm Res Oct 2011, 60(10):919-928.